AlloMune system

AlloMune™ system

A proprietary system designed to re-educate a recipient's immune system to accept a transplanted organ as its own, which is based on transplanting bone marrow (BM) from donor to recipient to establish mixed BM chimerism, allowing the recipient's body to recognise a donor organ as its own without needing long-term anti-rejection therapy.

The AlloMune system included conditioning of the recipient and treatment with MEDI-507 and enriched peripheral blood progenitor cells; post-transplant, patients are placed on short-term immunosuppressive therapy.
References in periodicals archive ?
Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
In late July BioTransplant announced it was implementing a restructuring plan intended to streamline the company's operations around its most promising proprietary products-the Allomune System and Eligix HDM Cell Separation technologies.
In the studies, miniature swine received a prototype of BioTransplant's AlloMune System and a 30 to 60 day course of cyclosporin as conditioning for a high-dose peripheral blood stem cell (PBSC) transplant from haploidentical donors.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
The AlloMune System is designed to allow long-term organ acceptance without the use of chronic immunosuppressive drugs.